Editorial Material
Urology & Nephrology
Matthew S. Ernst, Vishal Navani, J. Connor Wells, Frede Donskov, Naveen Basappa, Chris Labaki, Sumanta K. Pal, Luis Meza, Lori A. Wood, D. Scott Ernst, Bernadett Szabados, Rana R. McKay, Francis Parnis, Cristina Suarez, Takeshi Yuasa, Aly-Khan Lalani, Ajjai Alva, Georg A. Bjarnason, Toni K. Choueiri, Daniel Y. C. Heng
Summary: This study establishes real-world clinical benchmarks for immune-oncology (IO) and vascular endothelial growth factor targeted therapies (VEGF-TT) combination treatments in metastatic renal cell carcinoma (mRCC) patients, based on the International mRCC Database Consortium (IMDC) criteria.
Review
Oncology
Kevin K. Zarrabi, Oladimeji Lanade, Daniel M. Geynisman
Summary: Kidney cancer is a common type of cancer, with clear cell renal cell carcinoma being the most frequent form. Treatment options for newly diagnosed metastatic clear cell renal cell carcinoma include surgery, radiation, and systemic therapies. The complexity of treatment selection has increased due to the diverse biology of tumors. The therapeutic landscape for metastatic renal cell carcinoma has rapidly evolved, with combination therapy strategies involving immune checkpoint blockade and anti-angiogenesis targeted therapy becoming the standard of care.
Article
Oncology
Luca Ielasi, Francesco Tovoli, Matteo Tonnini, Bernardo Stefanini, Raffaella Tortora, Giulia Magini, Rodolfo Sacco, Tiziana Pressiani, Franco Trevisani, Ingrid Garajova, Fabio Piscaglia, Alessandro Granito
Summary: This study aimed to evaluate the prognostic role of different sites of metastases in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. The results showed that lymph nodes and lung metastases were associated with worse survival rates and treatment response, while bone and adrenal gland metastases did not significantly impact prognosis. Therefore, targeted treatment strategies should be considered for different metastatic sites.
Article
Oncology
Jonathan Heseltine, Jennifer Allison, Sam Wong, Kellati Prasad, Zhu-Chuen Oong, Helen Wong, Andrea Law, Natalie Charnley, Omi Parikh, Tom Waddell, Shien Chow
Summary: This study evaluated the outcomes of tivozanib in a real-world population of patients with metastatic renal cell carcinoma (mRCC). The results showed comparable activity and tolerability of tivozanib in this population, making it an attractive first-line option for patients who are unable to tolerate other targeted therapies or combination treatments.
Article
Oncology
Ana Elena Martin-Aguilar, Haide Nunez-Lopez, Juan C. Ramirez-Sandoval
Summary: Sequential inhibition of the VEGF pathway with sorafenib as a second-line therapy shows activity and tolerability in patients with metastatic RCC, especially benefiting those over 65 years old. Adverse events grade >= 3 were mainly observed in 29% of patients.
Review
Oncology
Shuchi Gulati, Chris Labaki, Georgia Sofia Karachaliou, Toni K. Choueiri, Tian Zhang
Summary: The treatment paradigm for metastatic clear cell renal cell carcinoma has changed dramatically in recent decades. Combinations of immune checkpoint inhibitors have become the first-line treatment for mccRCC. There are currently multiple first-line treatment options, and physicians need to consider various factors to determine the optimal treatment regimen.
Article
Oncology
L. Albiges, P. Barthelemy, M. Gross-Goupil, S. Negrier, M. N. Needle, B. Escudier
Summary: The combination therapy of tivozanib plus nivolumab showed tolerable adverse events profile and promising antitumor efficacy in both treatment-naive and previously treated metastatic RCC patients, with an objective response rate of 56% and disease control rate of 96%.
ANNALS OF ONCOLOGY
(2021)
Article
Urology & Nephrology
Kelly N. Fitzgerald, Cihan Duzgol, Andrea Knezevic, Natalie Shapnik, Ritesh Kotecha, David H. Aggen, Maria I. Carlo, Neil J. Shah, Martin H. Voss, Darren R. Feldman, Robert J. Motzer, Chung -Han Lee
Summary: There is no significant difference in outcomes between immunotherapy-based combinations and tyrosine kinase inhibitor/immune checkpoint inhibitor combination in the treatment of metastatic clear cell renal cell carcinoma (ccRCC), suggesting that the current treatment strategy should not be changed.
Review
Medicine, General & Internal
Dailong Li, Sha Wan, Wanqiang Li, Chunlai Cheng, Lu Xu, Peng Gu
Summary: Sorafenib demonstrates comparable efficacy to sunitinib as a first-line treatment for mRCC, but with lower toxicity.
Review
Oncology
Ameish Govindarajan, Daniela V. Castro, Zeynep B. Zengin, Sabrina K. Salgia, Jalen Patel, Sumanta K. Pal
Summary: The treatment landscape of metastatic renal cell carcinoma has changed significantly over the past decade, with doublet immunotherapy and combination therapy becoming the standard of care. This article outlines the important elements and considerations in the treatment of renal cell carcinoma and explores potential treatment options.
Review
Oncology
Mario Fontes-Sousa, Emiliano Calvo
Summary: Patients with sarcomatoid features in advanced or metastasized renal cell carcinoma (mRCC) show superior efficacy and survival outcomes when treated with immune checkpoint inhibitors (ICI) in combination therapy compared to tyrosine kinase inhibitors (TKI) in monotherapy, achieving overall response rates of 50-60%.
CANCER TREATMENT REVIEWS
(2022)
Review
Oncology
Yann-Alexandre Vano, Sylvain Ladoire, Reza Elaidi, Slimane Dermeche, Jean-Christophe Eymard, Sabrina Falkowski, Marine Gross-Goupil, Gabriel Malouf, Berangere Narciso, Christophe Sajous, Sophie Tartas, Eric Voog, Alain Ravaud
Summary: The first-line treatment options for metastatic clear cell renal cell carcinoma have significantly increased, with a recommended therapeutic strategy based on a combination, but the choice between dual immunotherapy or immunotherapy combined with an antiangiogenic drug is not clearly standardized. Multiple phase III trials have shown the superiority of combination therapy over monotherapy, but unresolved issues include the relevance of treatment options based on the patient's profile and consideration of subsequent treatments.
Review
Oncology
Yu-Wei Chen, Brian Rini
Summary: This review discusses the landmark trials and treatment options for metastatic clear cell renal cell carcinoma (mccRCC). Four immuno-oncology (IO)-based combinations, including IO/IO and IO/TKI, have shown overall survival benefit, but each has distinct efficacy and toxicity profiles. Factors such as patient tumor burden, performance status, and risk group influence the choice of IO-based treatment. Future studies should focus on identifying biomarkers to improve patient outcomes.
CURRENT ONCOLOGY REPORTS
(2022)
Article
Oncology
S. Aeppli, M. Schmaus, T. Eisen, B. Escudier, V Gruenwald, J. Larkin, D. McDermott, J. Oldenburg, C. Porta, B. Rini, M. Schmidinger, C. N. Sternberg, C. Rothermundt, P. M. Putora
Summary: In the first-line treatment of metastatic clear cell renal cell carcinoma, experts recommended various drugs and drug combinations based on different decision criteria and parameters, with significant inter-expert variations observed. This demonstrates how data from randomized trials are implemented differently in daily practice.
Article
Oncology
Elaine Chang, Chana Weinstock, Lijun Zhang, Mallorie H. Fiero, Miao Zhao, Eias Zahalka, Tiffany K. Ricks, Jeanne Fourie Zirkelbach, Junshan Qiu, Jingyu Yu, Xiao Hong Chen, Vishal Bhatnagar, Kirsten B. Goldberg, Shenghui Tang, Paul G. Kluetz, Richard Pazdur, Amna Ibrahim, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: On March 10, 2021, the FDA approved tivozanib for the treatment of relapsed or refractory kidney cancer patients. The approval was based on the TIVO-3 study, which showed that tivozanib had better efficacy compared to sorafenib and lower rates of adverse reactions.
CLINICAL CANCER RESEARCH
(2022)
Article
Urology & Nephrology
Ethan M. Basch, Mark Scholz, Johann S. de Bono, Nicholas Vogelzang, Paul de Souza, Gavin Marx, Ulka Vaishampayan, Saby George, James K. Schwarz, Emmanuel S. Antonarakis, Joseph M. O'Sullivan, Arash Rezazadeh Kalebasty, Kim N. Chi, Robert Dreicer, Thomas E. Hutson, Amylou C. Dueck, Antonia Bennett, Erica Dayan, Milan Mangeshkar, Jaymes Holland, Aaron L. Weitzman, Howard Scher
Article
Engineering, Biomedical
Joshua A. Adkinson, Bharat Karumuri, Timothy N. Hutson, Rui Liu, Omar Alamoudi, Ioannis Vlachos, Leonidas Iasemidis
IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING
(2019)
Article
Oncology
Cora N. Sternberg, Robert J. Motzer, Thomas E. Hutson, Toni K. Choueiri, Christian Kollmannsberger, Georg A. Bjarnason, Paul Nathan, Camillo Porta, Viktor Gruenwald, Luca Dezzani, Jackie Han, Nizar M. Tannir
CLINICAL GENITOURINARY CANCER
(2019)
Article
Oncology
Viktor Grunwald, Thomas Powles, Toni K. Choueiri, Thomas E. Hutson, Camillo Porta, Masatoshi Eto, Cora N. Sternberg, Sun Young Rha, Cixin S. He, Corina E. Dutcus, Alan Smith, Lea Dutta, Kalgi Mody, Robert J. Motzer
Meeting Abstract
Oncology
Brian I. Rini, Sumanta K. Pal, Bernard Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, David F. McDermott
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Meeting Abstract
Oncology
David F. McDermott, Brian I. Rini, Robert J. Motzer, Nizar M. Tannir, Bernard Escudier, Christian K. Kollmannsberger, Hans J. Hammers, Camillo Porta, Saby George, Frede Donskov, Howard Gurney, Marc-Oliver Grimm, Michael Roger Harrison, Thomas E. Hutson, Shuo Yang, Jennifer Johansen, Sumati Rao, Sabeen Fatima Mekan, Michael Rael, Thomas Powles
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Article
Oncology
Manuela Schmidinger, Aristotelis Bamias, Giuseppe Procopio, Robert Hawkins, Angel Rodriguez Sanchez, Sergio Vazquez, Narayanan Srihari, Haralabos Kalofonos, Petri Bono, Chaitali Babanrao Pisal, Yulia Hirschberg, Luca Dezzani, Qasim Ahmad, Eric Jonasch
Article
Biochemistry & Molecular Biology
Arnau Hervera, Luming Zhou, Ilaria Palmisano, Eilidh McLachlan, Guiping Kong, Thomas H. Hutson, Matt C. Danzi, Vance P. Lemmon, John L. Bixby, Andreu Matamoros-Angles, Kirsi Forsberg, Francesco De Virgiliis, Dina P. Matheos, Janine Kwapis, Marcelo A. Wood, Radhika Puttagunta, Jose Antonio del Rio, Simone Di Giovanni
Meeting Abstract
Oncology
Camillo Porta, Elena Verzoni, Bernard Escudier, Sumanta K. Pal, Michael B. Atkins, Thomas E. Hutson, Michael N. Needle, David F. McDermott, Brian I. Rini
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Meeting Abstract
Oncology
Hamid Emamekhoo, Mark Olsen, Bradley Curtis Carthon, Alexandra Drakaki, Ivor John Percent, Ana M. Molina, Daniel C. Cho, Johanna C. Bendell, Lucio N. Gordan, Arash Rezazadeh Kalebasty, Daniel J. George, Thomas E. Hutson, Richard J. Lee, Tina C. Young, Jennifer Johansen, Scott S. Tykodi
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Article
Neurosciences
Ilaria Palmisano, Matt C. Danzi, Thomas H. Hutson, Luming Zhou, Eilidh McLachlan, Elisabeth Serger, Kirill Shkura, Prashant K. Srivastava, Arnau Hervera, Nick O' Neill, Tong Liu, Hassen Dhrif, Zheng Wang, Miroslav Kubat, Stefan Wuchty, Matthias Merkenschlager, Liron Levi, Evan Elliott, John L. Bixby, Vance P. Lemmon, Simone Di Giovanni
NATURE NEUROSCIENCE
(2019)
Review
Clinical Neurology
Thomas H. Hutson, Simone Di Giovanni
NATURE REVIEWS NEUROLOGY
(2019)
Article
Oncology
Brian I. Rini, Sumanta K. Pal, Bernard J. Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, David F. McDermott
Article
Oncology
Brian Rini, Dena Battle, Robert A. Figlin, Daniel J. George, Hans Hammers, Tom Hutson, Eric Jonasch, Richard W. Joseph, David F. McDermott, Robert J. Motzer, Sumanta K. Pal, Allan J. Pantuck, David Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2019)
Meeting Abstract
Oncology
Thomas E. Hutson, M. Dror Michaelson, Timothy M. Kuzel, Neeraj Agarwal, Ana M. Molina, James J. Hsieh, Ulka N. Vaishampayan, Sharon Xie, Urmi Bapat, Rohit K. Jain, Mayer N. Fishman
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)